Diabetes and diabetic ketoacidosis are becoming increasingly common, which is a serious global concern. According to the National Library of Medicine, diabetic ketoacidosis is common in adults with type 1 diabetes, and one-third of people have serious diseases such as diabetes type 1 and diabetic ketoacidosis. Furthermore, healthcare providers are working to raise knowledge about type 1 diabetes and diabetic ketoacidosis. For example, Diabetes UK, an English healthcare and research charity, suggested in April 2020 that the National Health Service should be kept open for emergency diseases such as diabetic ketoacidosis because they can escalate to a life-threatening situation.
The global Diabetic Ketoacidosis Therapy Market is valued at USD 1,256.96 million in 2019, with a CAGR of 6.1% from 2017 to 2029.
Key Competitors in the Diabetic Ketoacidosis Treatment Industry:
1. Novo Nordisk A/S: Novo Nordisk is a multinational healthcare firm that manufactures and distributes insulin and other diabetic medications. The company creates and distributes insulin as well as other medicinal goods used to treat diabetes. Founded 1923. Bagsvaerd, Denmark, is the headquarters. Novo Nordisk today announced the completion of the acquisition of Forma Therapeutics Holdings, Inc. (Forma), which was announced on September 1, 2022.
2. Sanofi S.A: Therapeutics developer and distributor focusing on patient requirements. The company sells diabetic and cancer medications, as well as consumer healthcare items, animal health products, and human immunisations. Founded 1973. Headquarters are in Paris, France. Sanofi will purchase Provention Bio, bringing TZIELD, the first disease-modifying medication for the postponement of Stage 3 type 1 diabetes (T1D), to its portfolio.
3. Biocon Limited: Biocon Ltd is a biopharmaceutical business that creates disease-specific biotechnology treatments. The company's primary focus is on the development, production, and distribution of innovative and biosimilar medications for diabetes, cancer, and autoimmune diseases. The company was founded in 1978. Bengaluru, Karnataka, is the company's headquarters.
4. Tonghua Dongbao Pharmaceutical Co., Ltd: Tonghua Dongbao Pharmaceutical Co Ltd is based in China. It is involved in the manufacture and distribution of pharmaceutical products. Human insulin injection, heart and brain capsule, vitamin e soft capsule, and oral detoxification solutions are among its offerings. Founded 1992.
5. Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Inc is a pharmaceutical company that specialises in the research and development of pharmaceutical solutions, such as an oral insulin capsule for diabetes treatment and the use of orally ingestible capsules or pills for the delivery of other polypeptides. ORMD-0801 is a proprietary medicine that is an orally ingestible insulin capsules for diabetes treatment. Its other product is Oral Glucagon-like Peptide-1, an incretin hormone, a type of gastrointestinal hormone that promotes pancreatic insulin secretion. Founded 2006. Headquarters are located in New York, United States.
6. Pfizer Inc.: Pfizer is a global pharmaceutical company with yearly sales close to $50 billion (without COVID-19 product sales). While it used to sell a wide range of healthcare items and chemicals, prescription medications and vaccines now account for the vast majority of its sales. It was founded in 1848. Headquarters are in New York, USA. Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialise ARV-471, a PROTAC® Protein Degrader.
Definition: DKA develops when your body doesn't have enough insulin to allow blood sugar into your cells for use as energy.
